MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.570
+0.010
+0.39%
After Hours: 2.570 0 0.00% 16:00 07/10 EDT
OPEN
2.570
PREV CLOSE
2.560
HIGH
2.590
LOW
2.520
VOLUME
219.86K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
1.520
MARKET CAP
186.99M
P/E (TTM)
-3.8635
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CERC stock price target is 11.00 with a high estimate of 12.00 and a low estimate of 10.00.

EPS

CERC News

More
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
Michael Cola Is The CEO, President & Director of Cerecor Inc. (NASDAQ:CERC) And They Just Picked Up 132% More Shares
Simply Wall St. · 06/13 14:01
Largest Insider Trades of the Week
GuruFocus.com · 06/12 16:42
Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire · 06/11 18:30
Do Hedge Funds Love Cerecor Inc. (CERC)?
In this article we will check out the progression of hedge fund sentiment towards Cerecor Inc. (NASDAQ:CERC) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company befo
Insider Monkey · 06/10 20:18
Cerecor prices $33M equity offering, shares down 16% premarket
Seeking Alpha - Article · 06/09 13:30
CHK, CPE among premarket losers
Seeking Alpha - Article · 06/09 13:14
Cerecor Announces A Common Stock Offering; No Details Disclosed
Benzinga · 06/08 20:03

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CERC

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
More

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERC stock methods without spending real money on the virtual paper trading platform.